Publications by authors named "Fnu Sidra"
J Diabetes Complications
January 2025
Article Synopsis
- Atherosclerotic cardiovascular disease is a major health concern for individuals with type 2 diabetes (T2D) and chronic kidney disease (CKD), but GLP-1 receptor agonists (GLP-1RAs) can help reduce cardiovascular risks, improve blood sugar levels, and promote weight loss despite low usage rates due to safety concerns.
- In a retrospective study involving 236 patients, those taking GLP-1RAs showed a significantly greater average weight loss (-9.6%) and better reduction in HbA1c levels (-1.0%) after 36 months compared to those on dipeptidyl-peptidase 4 inhibitors (DPP-4is), who lost only -2.4
Article Synopsis
- Researchers studied the effects of glucagon-like peptide-1 receptor agonists (GLP1-RA) versus Dipeptidyl peptidase-4 inhibitors (DPP4i) in U.S. veterans aged 35 and older with chronic kidney disease (CKD) and type 2 diabetes (T2D) from 2006 to 2021.
- They aimed to see how these treatments affected healthcare usage, mortality rates, and cardiovascular events.
- Results showed that GLP1-RA use led to lower healthcare utilization and all-cause mortality rates without a significant difference in cardiovascular events after a follow-up period of about 2.2 years.
